Protein Engineering Drug Research

Protein Engineering Drug Research – Comprehensive Biophysical, Functional & Developability Assessment

You are searching for protein engineering drug research support because you need to perform this characterisation—whether to optimise binding affinity and specificity, improve biophysical stability, reduce immunogenicity risk, or accelerate the developability of engineered protein therapeutics (antibodies, scaffolds, fusion proteins, enzymes). We provide a complete research service that integrates high‑resolution structure determination, in silico design support, biophysical stability profiling, and functional activity validation to guide your protein engineering cycles from hit to lead and candidate.

What We Characterise – From Primary Sequence to Higher‑Order Structure & Aggregation Propensity

Our protein engineering drug research goes far beyond simple SDS‑PAGE or binding ELISA. Using high‑resolution mass spectrometry (intact mass, peptide mapping, disulfide bridge analysis, and post‑translational modification localisation), we confirm primary sequence integrity and correct processing with <0.05% mass error. For higher‑order structure, we deploy hydrogen‑deuterium exchange mass spectrometry (HDX‑MS) and circular dichroism (far‑UV and near‑UV CD) to monitor secondary and tertiary structure stability under thermal, pH, and mechanical stress. We quantify aggregation propensity using size‑exclusion chromatography coupled with multi‑angle light scattering (SEC‑MALS) and dynamic light scattering (DLS), detecting soluble aggregates as low as 0.05% and measuring hydrodynamic radius (R_h) with 0.1 nm precision. For conformational stability, we provide differential scanning fluorimetry (DSF) and nano‑differential scanning calorimetry (nano‑DSC) – reporting T_m (melting temperature), T_agg (aggregation onset), and ΔG of unfolding with reproducibility of ±0.2°C. In addition, we assess colloidal stability by measuring interaction parameter k_D (via DLS or self‑interaction chromatography), a key predictor of high concentration formulation behaviour.

How Deep We Go – Affinity Maturation, Developability Risk Assessment & In Silico Guided Engineering

We don't just measure single attributes. Our integrated pipeline includes affinity maturation support: surface plasmon resonance (SPR, Biacore 8K) or biolayer interferometry (BLI) to determine kinetic constants (k_on, k_off, K_D) from pM to mM for up to 96 engineered variants per run. For specificity and off‑target risk, we perform proteome microarray screening (20,000 human proteins) and polyreactivity assays (e.g., baculovirus particle binding, non‑specific tissue binding). To predict and reduce immunogenicity, we provide in silico T‑cell epitope mapping (NetMHCpan, IEDB) and in vitro CD4+ T‑cell activation assays using human PBMCs from 50+ HLA‑typed donors. For developability risk assessment, we combine sequence‑based tools (e.g., spatial charge distribution, aggregation propensity (SAP), isoelectric point (pI) calculation) with experimental measurements of solubility (high concentration stability up to 200 mg/mL), viscosity (microfluidic viscometer), and long‑term stability (3‑6 months at 4°C, 25°C, 40°C). We also offer protein surface engineering guidance: alanine scanning coupled with SPR to map hot spots, followed by site‑directed mutagenesis and re‑characterisation – typically reducing charge or hydrophobic patches that drive aggregation. For complex formats (bispecifics, fusion proteins, Fc‑variants), we perform subunit integrity analysis by non‑reducing SEC‑MS and native mass spectrometry to confirm correct assembly and absence of mis‑paired species.

Why Our Protein Engineering Drug Research Stands Out – Integrated Platform, High Throughput & Regulatory Alignment

1. End‑to‑end engineering support: We provide structure‑based design (homology modelling, docking, molecular dynamics simulations), expression (mammalian, E. coli, yeast), purification, and comprehensive characterisation under one roof – saving you multiple CRO contracts.
2. High‑throughput variant screening: Our automated SPR (Biacore 8K) and BLI (Octet R8) systems screen up to 384 engineered variants per 24 hours for binding kinetics. We also offer multi‑attribute method (MAM) by LC‑MS to simultaneously monitor sequence variants, glycosylation, oxidation, deamidation, and aggregation in a single injection.
3. Deep biophysical characterisation for challenging candidates: For pH‑sensitive, membrane‑protein, or unstable engineered proteins, we use HDX‑MS to map conformational dynamics and cryo‑EM (at 3‑4 Å resolution) for large complexes – enabling observation of subtle structural changes due to mutations.
4. Immunogenicity risk mitigation: Our in silico + in vitro (T‑cell assay) workflow has been validated with >50 clinical‑stage antibodies. We also measure anti‑drug antibody (ADA) risk by surface plasmon resonance (SPR) with polyclonal human IgG enrichment.
5. Regulatory‑ready data packages: All reports follow ICH Q6B, Q5C, and M4 guidance. We have supported nine IND/CTA filings for engineered proteins (bispecifics, half‑life extended variants, immune agonists). Turnaround: single variant characterisation (affinity+stability): 1‑2 weeks; full engineering cycle (design‑express‑characterise 20 variants): 4‑6 weeks.

Who Relies on Our Protein Engineering Drug Research – Real‑World Impact

A biotech company developing a half‑life extended Fab fragment used our HDX‑MS and DSC to compare three Fc‑fusion variants – we identified a 4‑amino acid linker that maintained parent Fab dynamics while increasing T_m by 11°C, leading to a clinical candidate. Another client working on a bispecific T‑cell engager (BiTE) with aggregation issues performed our SAP analysis and charge engineering – we reduced aggregation from 15% to 0.8% after two rounds of mutagenesis (three surface mutations) while retaining picomolar affinity. A large pharma used our developability risk assessment panel (25 assays) to rank 12 initial lead candidates; the top‑ranked molecule showed no aggregation at 150 mg/mL, viscosity <10 cP, and no T‑cell epitopes in >100 donor alleles – selected as their development candidate. An academic group studying engineered enzyme therapeutics relied on our kinetic characterisation (k_cat, K_m) before and after engineering – we measured a 40‑fold increase in catalytic efficiency and confirmed structural integrity by CD and HDX‑MS.

Ready to Start Your Protein Engineering Drug Research Project?

Send us gene sequences or plasmids for expression, purified protein (≥1 mg for full characterisation, ≥100 μg for binding screen), or crude lysates (≥5 mL). We will perform expression optimisation (optional), purification, binding kinetics, biophysical stability profiling, immunogenicity risk assessment, and optional structure‑guided engineering – delivering a comprehensive report with actionable recommendations for next‑round design within 2‑6 weeks depending on scope. Request a free consultation; we will design an integrated protein engineering characterisation plan (affinity maturation, stability improvement, or developability ranking) tailored to your therapeutic modality and target product profile.